Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Healthy adult males age 18 - 50 years, BMI 19-32 kg/m2~* Acceptable duration of cold pain test results at screening~Exclusion Criteria:~* Clinically significant medical illness or physical exam findings~* Active dermatological conditions or skin trauma on the non-dominant hand, or peripheral vascular disease~* Partial blindness, keratoconus, nystagmus or any other ophthalmic condition which could interfere with pupillometry~* Use of tobacco or nicotine within 6 months prior to screening~* History of recent (within 6 months) drug or alcohol abuse, as defined in DSM-IV-TR

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- TRV130 1.5 mg (Type: EXPERIMENTAL): TRV130 1.5 mg IV x 1 dose
- TRV130 3 mg (Type: EXPERIMENTAL): TRV130 3 mg IV x 1 dose
- TRV130 4.5 mg (Type: EXPERIMENTAL): TRV130 4.5 mg IV x 1 dose
- Morphine (Type: ACTIVE_COMPARATOR): Morphine 10 mg IV x 1 dose
- Placebo (Type: PLACEBO_COMPARATOR): Dextrose 5% in water IV x 1 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).